Sign in with your PharmaBlock account:
|
|
|
For some years, the pharmaceutical industry has been experiencing a crisis of low R&D productivity in terms of number of approved new chemical entities (NCEs). The emergence of new technologies and business models in R&D has yet led to higher success rate in drug discovery. As an innovation- and knowledge-based chemistry service company, PharmaBlock strives to provide customers with ...
2010-1-19
PharmaBLOCK will attend INFORMEX® 2010 from 16th to 19th, February in San Francisco. Mr. Yaojun Wu, the chairman of PharmaBLOCK, Dr. John Hill and Mr. Yi Li, both directors of Sales and Business Development......
|
2009-11-28
At the beginning of December, Dr. WU Xihan will join PharmaBLOCK as the president of research. Dr. WU got his Ph.D. degree from Shanghai Institute of Materia Medica in the Chinese Academy of Sciences ......
|
|
|
PharmaBlock specialized in the design and synthesis of biologically-biased scaffolds ...
|
| |
With our expertise in synthetic and medicinal chemistry and with our deep understanding...
|
| |
Large scale synthesis is a particular strength of PharmaBlock. In house we have 1 process laboratory with……
|
|